What is the proposed transaction between Pfizer and Wyeth?

Pfizer Inc. has entered into a definitive Agreement and Plan of Merger to acquire Wyeth. The transaction involves Pfizer's subsidiary, Wagner Acquisition Corp., merging with Wyeth. Wyeth will survive as a wholly-owned subsidiary of Pfizer.

What will Wyeth shareholders receive in the merger?

Wyeth shareholders will receive $33.00 in cash and 0.985 shares of Pfizer common stock for each share of Wyeth common stock they own. Certain restricted shares and shares held by the companies or subject to appraisal rights will be treated differently.

How is Pfizer financing this acquisition?

Pfizer has secured committed financing for the merger. This includes a $22.5 billion unsecured bridge term facility and a commitment for a portion of a $4.0 billion unsecured revolving credit facility. The financing is subject to various closing conditions, including maintaining specific credit ratings.

What are the key conditions for the merger to be completed?

The completion of the merger is subject to several conditions, including the adoption of the merger agreement by Wyeth's stockholders, obtaining necessary antitrust approvals (including under the Hart-Scott-Rodino Act), the accuracy of representations and warranties, the effectiveness of Pfizer's Form S-4 registration statement, and the satisfaction of specified financing conditions by Pfizer's lenders.

Are there any potential penalties if the deal does not close?

Yes, the merger agreement includes provisions for termination fees. For instance, if Wyeth terminates the agreement to accept a superior proposal, it may owe Pfizer $1.5 billion or $2 billion depending on timing. If Pfizer fails to secure financing and does not close the merger, it may owe Wyeth a $4.5 billion termination fee. Significant fees are also associated with changes in Wyeth's board recommendation or breaches of the agreement.

PFE 8-K: Material Agreements

Summary

Pfizer Inc. has announced a definitive Agreement and Plan of Merger with Wyeth, dated January 25, 2009. This filing details the terms of the proposed merger, where Pfizer will acquire Wyeth through its wholly-owned subsidiary, Wagner Acquisition Corp. The transaction is structured as a stock and cash deal, with Wyeth shareholders set to receive $33.00 in cash and 0.985 shares of Pfizer common stock for each share of Wyeth's common stock they hold. This significant acquisition aims to expand Pfizer's portfolio and market presence. The merger is subject to customary closing conditions, including regulatory approvals, the adoption of the agreement by Wyeth's stockholders, and financing arrangements. Pfizer has secured committed financing for the transaction, including a $22.5 billion bridge term facility and a $4.0 billion revolving credit facility. The company has also outlined potential termination fees under various scenarios, highlighting the financial implications for both parties should the deal not close as planned. This event represents a major strategic move for Pfizer in the pharmaceutical landscape.

Key Highlights

1Pfizer Inc. entered into a definitive Agreement and Plan of Merger with Wyeth on January 25, 2009.
2The proposed merger will be a stock and cash transaction, with Wyeth shareholders receiving $33.00 in cash and 0.985 shares of Pfizer common stock per Wyeth share.
3Pfizer has secured significant financing commitments for the acquisition, including a $22.5 billion bridge term facility and a $4.0 billion revolving credit facility.
4The merger is contingent upon several conditions, including regulatory approvals, adoption by Wyeth's shareholders, and the satisfaction of financing conditions.
5The agreement includes provisions for termination fees, with significant amounts payable by either party under specific circumstances, such as Wyeth receiving a superior proposal or Pfizer failing to secure financing.
6Pfizer has agreed to appoint two current Wyeth directors to its board upon completion of the merger.
7The filing includes forward-looking statements regarding the potential benefits and risks associated with the merger, emphasizing the possibility of integration challenges and regulatory hurdles.

PFIZER INC 8-K Report, Material Agreement (Jan 29, 2009)

Summary

Key Highlights

Frequently Asked Questions